A Phase Ib/II, Open Label, Proof-of-concept Study of Sabatolimab and Magrolimab-based Therapy for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Magrolimab (Primary) ; Sabatolimab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 09 Apr 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Sep 2022 Planned End Date changed from 20 Jul 2027 to 26 Oct 2029.
- 02 Sep 2022 Planned primary completion date changed from 20 Jul 2027 to 26 Oct 2029.